Please login to the form below

Not currently logged in
Email:
Password:

Trial results on flu vaccine co-administration

Results of a trial to assess co-administration of Pandemrix and Fluarix in adults shows a strong response
GlaxoSmithKline (GSK) has announced the results of a clinical trial to assess its adjuvanted H1N1 pandemic influenza vaccine, Pandemrix, when administered in conjunction with Fluarix, the annual seasonal influenza vaccine. The annual seasonal influenza vaccine contains three strains of influenza identified by public health organisations, but for the Northern Hemisphere 2009/2010 influenza season, the composition of the seasonal influenza vaccine was determined before the appearance of the H1N1 strain.

The trial, involving 168 adults over the age of 60 years, was designed to evaluate the tolerability and immunogenicity of the co-administration of Pandemrix and Fluarix, and showed that one dose of both vaccines in separate arms induces a strong response for both the H1N1 pandemic vaccine and the seasonal vaccine. The results confirmed previously reported findings in an elderly population that the immune response elicited by Pandemrix exceeded the immunogenicity criteria as defined by international licensing authorities for a pandemic influenza vaccine. The strong immune response to the seasonal influenza vaccine demonstrated in the trial also exceeded the three immunogenicity criteria as defined by international licensing authorities for a seasonal trivalent vaccine.

According to Jean Stephénne, president of GSK Biologicals, this data could  simplify the influenza vaccination programmes that countries are beginning to implement. “This provides valuable insight into vaccination in this specific age group that generally benefits from the annual seasonal vaccination,” Mr Stephenne said.

9th November 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcare Media Europe – HME

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

The Holy Grail of HCP Access
This is the data you need to gain access....
No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....

Infographics